Sign up USA
Proactive Investors - Run By Investors For Investors

DNA Vaccine maker Inovio to present at multiple conferences

DNA Vaccine maker Inovio to present at multiple conferences

Inovio Pharmaceuticals (NYSE:INO), developer of synthetic vaccines against cancers and infectious diseases, reported on Friday that company advisors, collaborators and scientists are scheduled to present at several scientific conferences.

David Weiner will make his presentation on DNA vaccines and T cell responses in humans and animals that induce neutralizing immune responses, at the Marriott Waterfront Hotel on Oct. 2, Seattle.

A day after, product development scientist, Matt Morrow, will make a presentation on induction of Human papillomavirus (HPV) specific CTLs, or killer T cells, in humans after DNA immunization. 

Further, a second conference called Cancer Immunotherapy is taking place at the Millennium Broadway and Conference Centre, in New York.

Mark Bagarazzi, Chief Medical Officer, will make his presentation on Oct. 6 on the topic of delivering potent and durable immune responses with HPV 16 and 18, as well as DNA vaccines through electroporation.  

Bagarazzi is scheduled to make another lecture at the World Vaccine Congress on Oct. 11 in France where he will discuss the future of "Holy Grail" vaccines.

A skin vaccination summit will take place on Oct. 12 to 14 at the Kellogg Conference Hotel in Washington, D.C. 

Kate Broderick of research and development is set to make her presentation on Oct. 13 and will talk about DNA delivery to skin is enhanced by next-generation devices that target dermal tissue. Niranjan Sardesai also from research and development will talk about vaccines for emerging infectious diseases, making his presentation on Oct. 14.

Finally, the fifth conference at Providence, Rhode Island and is scheduled for Oct. 17 to 19. 

Niranjan Sardesai of research and development will present at the Vaccines Renaissance Conference discussing induction of HPV specific CTLs in humans after DNA immunotherapy on Oct. 18.

Blue Bell, Pennsylvania-based Inovio Pharmaceutical, formerly Inovio Biomedical Corp, is developing next generation vaccines, known as DNA-based vaccines, to treat and prevent cancers and infectious diseases. Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.

Register here to be notified of future INO Company articles
View full INO profile View Profile

Inovio Pharmaceuticals Timeline

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use